header logo image


Page 206«..1020..205206207208..220230..»

Rheumatoid arthritis and diabetes: Link, prevention, treatment – Medical News Today

August 30th, 2021 1:56 am

Rheumatoid arthritis (RA) is a type of inflammatory arthritis and autoimmune disorder. People with RA have an increased risk of diabetes, while diabetes can also raise the risk of RA. Excessive inflammation, lifestyle factors, and genetics may be among the factors that connect the two conditions.

RA and diabetes also share several risk factors and causes, including certain medications.

This article discusses the link between RA and diabetes and explains how people can prevent and treat each of these conditions.

Although diabetes and RA share some similarities in terms of their causes and risk factors, they are very different conditions.

RA is an inflammatory autoimmune disease in which the bodys immune system mistakenly attacks healthy cells and tissue. It often causes inflammation in the joints of the hands, knees, or wrists. In some cases, it may affect the lungs, heart, eyes, or other organs throughout the body.

Type 2 diabetes is the most common form of diabetes. In a person living with the condition, the body either does not produce enough insulin or does not use it effectively. In either case, blood sugar levels will elevate.

The most likely connection between type 2 diabetes and RA involves inflammation and a buildup of cytokines known as tumor necrosis factor (TNF) in the body. The Arthritis Foundation notes that TNF plays a necessary role in wound healing by causing an inflammatory effect. However, it can be harmful when too much TNF is circulating in the body.

In RA, the immune systems attack on the joints causes TNF to build up in the body. In type 2 diabetes, fat cells mainly produce TNF, which can cause the body to develop insulin resistance over time. As a result, it is possible that the inflammation and TNF associated with RA could increase the risk of a person developing type 2 diabetes.

Other possible connections between RA and type 2 diabetes involve medications and lifestyle factors that can act as risk factors for both conditions.

Certain medications, such as corticosteroids, can increase the likelihood of developing type 2 diabetes. Also, RA might lead to a person having a more sedentary lifestyle, which is a risk factor for type 2 diabetes.

People living with type 1 diabetes may also be at higher risk of developing RA and vice versa.

The Global Healthy Living Foundation, a nonprofit organization, explains that type 1 diabetes is an autoimmune disorder in which the immune system mistakenly attacks insulin-producing cells. It notes that a person living with one autoimmune disorder has an increased chance of developing a second one at some point in their lifetime.

People living with RA may have an increased risk of developing type 2 diabetes. Researchers have found that people living with RA are 23% more likely to develop type 2 diabetes compared with the general population.

In a 2020 review, researchers noted that RA can negatively affect a persons insulin resistance, which can cause the body to develop more fat. They also reported that many people with RA who develop type 2 diabetes also have other risk factors, including obesity.

People living with RA may be more likely to develop type 1 diabetes, as both conditions are autoimmune disorders. A person who has an autoimmune condition is more likely to develop another one during their lifetime.

The Arthritis Foundation suggests that people over the age of 45 years get screenings for diabetes every 3 years, noting that this is particularly important for those living with RA.

Learn more about risk factors for type 2 diabetes.

People living with type 1 diabetes have a higher risk of developing RA. In part, this may be due to both conditions being autoimmune disorders. There also may be a genetic link between the two conditions research has shown that the gene PTPN22 is linked to both conditions.

Some researchers believe that the inflammation associated with type 2 diabetes triggers RA in people who are genetically predisposed. A 2014 study in Taiwan supports this theory, finding that living with type 2 diabetes increases the risk of RA in females.

It is unclear whether type 1 or 2 diabetes could make RA symptoms worse. However, similar lifestyle changes can help both conditions, including:

Doctors can help create an effective treatment plan for a person living with RA, diabetes, or both.

A doctor can recommend a combination of medications alongside self-care strategies to slow the progression of RA and prevent joint damage. The CDC says that possible strategies for people living with RA include:

Learn some tips for dealing with rheumatoid arthritis flare-ups here.

The Arthritis Foundation notes that treating a person living with RA and type 2 diabetes is not much different than treating a person living with RA alone. One of the most important aspects for a person living with both conditions is to get regular exercise to help prevent heart disease.

A doctor may recommend a combination of medications and lifestyle adjustments to manage diabetes. In some cases, a person may find that diet and exercise modifications are enough to control their blood sugar.

If a person cannot control their blood sugar with diet and exercise alone, a doctor may recommend medication. They may recommend drugs to help the body process sugar or prescribe insulin.

Read a review of therapies and lifestyle changes for diabetes here.

RA and diabetes share some similar features, and a person with one condition may have an increased risk of the other.

People living with type 1 diabetes may have an increased risk of RA, and vice versa, due to the connection between autoimmune disorders and genetics. The inflammation associated with type 2 diabetes may put individuals with this form of diabetes at higher risk of RA. RA can make a person more likely to develop type 2 diabetes by affecting their insulin resistance.

A person living with RA should get regular screenings and watch for warning signs of diabetes. A person with a diagnosis of type 2 diabetes should follow their doctors treatment advice.

See original here:
Rheumatoid arthritis and diabetes: Link, prevention, treatment - Medical News Today

Read More...

Drug used to treat rheumatoid arthritis and COVID-19 in short supply – KSL.com

August 30th, 2021 1:56 am

A medication used widely in treating rheumatoid arthritis is out of stock due to a rise in COVID-19 hospitalizations, affecting patients in the U.S. and Utah. (Adam Sotelo, KSL-TV)

SALT LAKE CITY A medication used widely in treating rheumatoid arthritis is out of stock due to a rise in COVID-19 hospitalizations, affecting patients in the U.S. and Utah.

Sharon Greenwood, of Utah County, was diagnosed with rheumatoid arthritis when she was just 12 years old.

"There is no cure," Greenwood said. "Even if (arthritis) gets in your jaw, then eating is a problem because you can't chew."

Decades later and a dozen or so failed treatments, Greenwood finally has a medication that works for her tocilizumab, known by the brand name Actemra. She has been using the treatment for 10 years.

"Without it, the pain is completely debilitating," Greenwood explained.

However, Greenwood says her monthly treatment is now out of reach.

"I went in for my treatment on Wednesday with the hospital," Greenwood said that's when her nurse at Intermountain American Fork Hospital told her there was a major shortage.

"Apparently, just that morning, the drug had been called in. The nurses were told they were not to use it for anyone because it was being confiscated and gathered up to be sent to a central location," Greenwood said.

Greenwood said she was one of the last rheumatoid arthritis patients to get their treatment.

"The nurse apparently had my drug in her hand and the pharmacist said 'No, we have to take that,' and she said 'No, our patient is here waiting for it,'" she said.

#EXCLUSIVE- "There's no guarantee," Hundreds of patients... are out of crucial treatment for rheumatoid arthritis, Actemra. @genentech says surge in #COVID19 hospitalizations is to blame for unsatiable demand...& it's affecting Utahns like Sharon Greenwood. Story now on @KSL5TVpic.twitter.com/CbQz5nPGHI

Greenwood said nurses told her the drug was going to be reserved for COVID-19 and possibly cancer patients as the delta variant fuels a surge in virus cases and hospitalizations.

"They told me they were hoping to have more come in in about 4-6 weeks, which will be around the time I have my next appointment, but there's no guarantee," Greenwood said, explaining that she is worried about the possibility of not getting her next treatment.

On June 24, the FDA issued an emergency use authorization for Actemra to treat COVID-19 patients in hospitals, including adults and kids age 2 and older.

"The EUA is based on results from four randomized, controlled studies that evaluated Actemra for the treatment of COVID-19 in more than 5,500 hospitalized patients. The results of these studies suggest that Actemra may improve outcomes in patients receiving corticosteroids and requiring supplemental oxygen or breathing support," said a company spokesperson for Genentech, the U.S. manufacturer of Actemra.

Genentech is the sole manufacturer and supplier of the drug in the U.S. Its parent company, Roche, manufactures the drug outside of the U.S.

However, despite efforts to ramp up production, Genentech confirmed in a written response to KSL, "they're experiencing a temporary stock out" of the drug in the U.S. since Aug. 16.

A company spokesperson added they expect to receive scheduled replenishments by the end of August. However, they warned, if the pandemic continues to spread at its current pace, there could be more shortages in weeks and months ahead.

"The dramatic emergence of the COVID-19 delta variant, as well as the unexpected slowing of vaccination rates in the U.S., has led to an overwhelmingly high incidence of COVID-19 hospitalizations in certain areas of the country. This new wave of the pandemic has led to Genentech experiencing an unprecedented demand for Actemra IV well-over 400% of pre-COVID levels over the last two weeks alone and it continues to increase," said Lindsey Mathias, senior manager of Genentech corporate relations.

In the meantime, Greenwood said her doctor and nurses told her the drug is being stockpiled and rationed priority is going to COVID-19 patients.

"For me, it's about quality of life. But for them, it's a matter of life or death, and so it does need to go to them first because they are the greater need," Greenwood said.

Nevertheless, Greenwood said the situation underscores the impact of others' choice not to be vaccinated as Intermountain experts have previously stated 90% of hospitalized COVID-19 patients are unvaccinated.

"Unless you suffer from rheumatoid arthritis, you may never know that choosing not to be vaccinated is affecting people like me," Greenwood said, "My hope is that people would choose wisely."

The World Health Organization, in conjunction with UnitAid, released a statement last week calling on the company to ensure equal access to the medicine and look for ways to increase global supplies.

KSL's Garna Mejia is also in contact with Intermountain Healthcare, Greenwood's health care provider, for more information on what exactly the supply shortage looks like in Utah. An update is expected later this week.

The most updated information on the U.S. supply of Actemra can be found here, while information on world supplies can be found here.

Read more:
Drug used to treat rheumatoid arthritis and COVID-19 in short supply - KSL.com

Read More...

Poverty Tied to Worse Functional Status in Rheumatoid Arthritis – HealthDay News

August 30th, 2021 1:56 am

TUESDAY, Aug. 24, 2021 (HealthDay News) -- Worse functional status and increased probability of functional decline are seen for patients with rheumatoid arthritis (RA) with lower socioeconomic status (SES), according to a study published online Aug. 4 in JAMA Network Open.

Zara Izadi, M.Pharm., from the University of California in San Francisco, and colleagues examined the association between SES and functional status in patients with RA using data from the American College of Rheumatology's Rheumatology Informatics System for Effectiveness registry. Data were included for 83,965 patients with a confirmed RA diagnosis who were seen at participating rheumatology practices.

The researchers found that the mean functional status score was worse at lower SES levels for all measures (e.g., Multidimensional Health Assessment Questionnaire quintile 1 and 5: 1.79 and 2.43, respectively). The probability of functional decline was 14.1 and 18.9 percent in the highest and lowest SES quintile, respectively, in longitudinal analyses. Disease activity partially mediated the association between SES and functional decline (7 percent).

"We found important disparities in functional status by SES in a national cohort of individuals with RA, despite utilization of rheumatology care," the authors write. "Future qualitative research is important to further our understanding of factors that affect functional status, including factors outside of medical care that can be intervened on."

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text

Read this article:
Poverty Tied to Worse Functional Status in Rheumatoid Arthritis - HealthDay News

Read More...

Mississippi hospitals dealing with global shortage of arthritis drug tocilizumab used to treat severely ill COVID-19 patients Mississippi hospitals…

August 30th, 2021 1:56 am

COLUMBUS, Miss. (WCBI) As hospitals across Mississippi and around the country continue to deal with high numbers of COVID-19 patients, yet another one of their resources is running low.

One of the challenges we face is, How do we treat patients in a consistent fashion?' says North Mississippi Health Services Chief Medical Officer Dr. Jeremy Blanchard.

The U.S. Food and Drug Administration approved tocilizumab for emergency use in late June. Two months later, a global shortage of the drug has drawn the concern of the World Health Organization.

Sometimes either those medications or our testing supplies have come at risk, Dr. Blanchard says. Most recently, we have one of our medicationsthat we use with severe respiratory dysfunctions that has a threatened supply chain right now.

The WHO says tocilizumab can play a key part in keeping patients alive and reducing the need for mechanical ventilation for the severely ill.

Very similar to the hydroxychloroquine family (of drugs) used in rheumatoid arthritis, says Hank Norwood, a pharmacist for Allegro Family Clinics.

Now Mississippi hospitals must rely on alternatives.

The steroid inhalers, the steroid packs, the antibiotic packs, and the breathing inhalers, Norwood says.

Dr. Jeremy Blanchard says NMHS hospitals have algorithms to help guide them in choosing the best treatment for a patient.

What they are is, if A happens then do B and if B happens then you do C, he explained. Its based on a positive test and a set of symptoms that says you have COVID.

But Dr. Blanchard says the best way to treat COVID is still to prevent someone from getting it.

If you were going to look at what evidence do we have that really has been effective in treating and managing COVID, the three biggies that come up first are going to be vaccination, masking and monoclonal antibodies, he says.

The WHO says it is working to expand the number of manufacturers of tocilizumab across the globe.

Continue reading here:
Mississippi hospitals dealing with global shortage of arthritis drug tocilizumab used to treat severely ill COVID-19 patients Mississippi hospitals...

Read More...

Effect of Introducing Biologics to Patients with Rheumatoid Arthritis on the Risk of Venous Thromboembolism: a Nationwide Cohort Study – DocWire News

August 30th, 2021 1:56 am

In the United States, 100,000-300,000 patients die from venous thromboembolism (VTE) each year, with more than 500,000 people related hospitalizations. While in Europe, 500,000 people die from VTE each year. Patients with rheumatoid arthritis are at increased risk of VTE. The use of biologics in patients with rheumatoid arthritis may be associated with an increased risk of VTE. We identified all patients who had been newly approved for Catastrophic Illness Card of rheumatoid arthritis extracted the claims data from the National Health Insurance research database and Registry for Catastrophic Illness Patient Database from 2003 to 2016. VTE was defined as the presence of inpatient VTE diagnostic codes (including DVT or PE) according to the discharge diagnosis protocol. An analysis of VTE variables indicated that the incidence of VTE in the biologic group (14.33/10,000 person-years) was higher than that in the conventional drug group (12.61/10,000 person-years). As assessed by the Cox proportional hazards model, the relative HR for VTE in the biologic group (HR: 1.11; 95% CI 0.79-1.55) versus that in the conventional drug group did not reach a significant difference. In conclusion, this study found no significant differences in risk were observed between the use of conventional DMARDs and biologics.

Read more:
Effect of Introducing Biologics to Patients with Rheumatoid Arthritis on the Risk of Venous Thromboembolism: a Nationwide Cohort Study - DocWire News

Read More...

East Lake valedictorian goes to Harvard to study medicine and cure moms arthritis – WTSP.com

August 30th, 2021 1:56 am

Lorena Britton and her mother, Rosa, moved to Boston this month. It marked the fulfillment of a goal the teen set over a decade ago: to attend Harvard University.

TARPON SPRINGS, Fla. Lorena Britton still remembers the moment she found out she would be attending her dream school.

That was December 17, the teen said. That was just like the best day of my life. We got the news at 7 p.m. and I stayed up all night.

The East Lake High School class of 2021 valedictorian only applied to one university. Attending Harvard had always been her goal since the day she came home from elementary school and asked her mother, Rosa, which school was the best in the nation. They even took a trip to Boston when Lorena was eight years old.

Weve had this mutual goal of getting there, said Lorena. Its such a special place to be.

Now, they both are there.

Im very proud, said Rosa, whom her daughter describes as her biggest cheerleader. So far, she hasnt let me down.

In mid-August, Lorena and Rosa packed up everything they owned and left Florida for Boston. It took four days to make the drive from the Sunshine State due to Rosas health issues. Shes been living with increasingly debilitating rheumatoid arthritis since she was 22 years old.

Brushing my teeth is hard, said Rosa, who emigrated from Venezuela knowing very little English two decades ago.

Lorena has been the caretaker for her mother for the last 8-10 years, helping with everyday tasks most able-bodied people take for granted. Her mothers arthritis has gotten progressively worse.

Thats why Lorena chose Harvard.

Its mostly the reason I want to be a doctor to help people like her, said Lorena. I just love learning.

Rheumatoid arthritis has attacked Rosas joints. She has limited mobility and is in constant pain. Lorena hopes her studies in regenerative biology at Harvard will lead to finding a breakthrough treatment or cure for her mothers physical issues.

Its been attacking me very aggressively. I cannot use my hands. I keep my spirits up and try to do my best, be happy, and all I can do is pray to God to see my Lorenas success, said Rosa. My life has been like a trial of fire.

Classes begin on September 1 for Lorena. She is eager to get back to the classroom. For a decade shes been dreaming of this day.

For herself, and her mother.

With modern science and stem cells we can probably find a cure for my moms disease, Lorena said. We depend on each other.

Lorena was awarded $2,000 from Achieva after the credit union heard about her story. Achieva has awarded $26,000 in scholarship funds this year, bringing its total to more than $200,000 in scholarships in the past 14 years.

Lorena plans to get a degree in developmental and regenerative biology.

View post:
East Lake valedictorian goes to Harvard to study medicine and cure moms arthritis - WTSP.com

Read More...

Incidence of Venous Thromboembolism in Rheumatoid Arthritis, Results from a "Real-life" Cohort and an Appraisal of Available Literature -…

August 30th, 2021 1:56 am

Background and Purpose

Rheumatoid arthritis (RA) is associated with an increased risk of venous thromboembolism (VTE) occurrence. In this work, we assessed the incidence and predictive factors of VTE in our real-life cohort of RA patients. To contextualize our results, we reviewed the available literature about this topic, we performed a retrospective analysis of prospectively followed-up patients with RA attending our Rheumatologic Clinic between January 2010 and December 2020.

Each patient was investigated for VTE occurrence. Incident cases were reported as incidence proportion and incidence rate per 1000 person-years at risk. Possible predictive factors were also exploited by regression analyses. Available literature about this topic was also assessed.

In this evaluation, 347 consecutive patients without previous evidence of VTE, attending our Rheumatologic Clinic from 2010 to 2020, were studied. In our real-life cohort, the incidence proportion of VTE was 3.7% (2.7-4.7%) and considering over 1654 person-years, an incidence rate of 7.8 1000 (2.5-11.7). Exploratively assessing predictive factors in our cohort, older age (hazard ratio [HR] 1.07, 95% confidence interval [CI] 1.01-1.14, p = .015), higher body mass index (HR 1.37, 95% CI 1.04-1.80, P = .026), and longer disease duration (HR 1.11, 95% CI 1.03-1.20, P = .006) resulted to be significant predictors of VTE occurrence during the follow-up.In our real-life cohort, VTE burden has been suggested in patients with RA.

Comparing our results with previous data derived from randomized controlled trials and administrative data, some different findings were retrieved about incidence of VTE. Assessing predictive factors, older age, higher body mass index, and longer disease duration resulted to be significant predictors of VTE occurrence during the follow-up. Taking together these observations, a further evaluation of this issue on specific designed studies is needed to provide more generalizable results to the daily clinical practice.

Continue reading here:
Incidence of Venous Thromboembolism in Rheumatoid Arthritis, Results from a "Real-life" Cohort and an Appraisal of Available Literature -...

Read More...

Animal Expert Shares 5 Things That Will Help Your Dog Live a Longer, Healthier Life – ScienceAlert

August 30th, 2021 1:55 am

As anyone who has ever lived with a dog will know, it often feels like we don't get enough time with our furry friends. Most dogs only live around ten to 14 years on average though some may naturally live longer, while others may be predisposed to certain diseases that can limit their lifespan.

But what many people don't know is that humans and dogs share many genetic similarities including a predisposition to age-related cancer. This means that many of the things humans can do to be healthier and longer lived may also work for dogs.

Here are just a few ways that you might help your dog live a longer, healthier life.

One factor that's repeatedly linked with longevity across a range of species is maintaining a healthy bodyweight. That means ensuring dogs aren't carrying excess weight, and managing their calorie intake carefully.

Not only will a lean, healthy bodyweight be better for your dog in the long term, it can also help to limit the impact of certain health conditions, such as osteoarthritis.

Carefully monitor and manage your dog's bodyweight through regular weighing or body condition scoring where you look at your dog's physical shape and "score" them on a scale to check whether they're overweight, or at a healthy weight. Using both of these methods together will allow you to identify weight changes and alter their diet as needed.

Use feeding guidelines as a starting point for how much to feed your dog, but you might need to change food type or the amount you feed to maintain a healthy weight as your dog gets older, or depending on how much activity they get.

Knowing exactly how much you are feeding your dog is also a crucial weight-management tool so weigh their food rather than scooping it in by eye.

More generally, good nutrition can be linked to a healthy ageing process, suggesting that what you feed can be as important as how much you feed. "Good" nutrition will vary for each dog, but be sure to look for foods that are safe, tasty and provide all the nutrients your dog needs.

Exercise has many physiological and psychological benefits, both for our dogs (and us). Physical activity can help to manage a dog's bodyweight, and is also associated with anti-ageing effects in other genetically similar species.

While exercise alone won't increase your dog's lifespan, it might help protect you both from carrying excess bodyweight. And indeed, research suggests that "happy" dog walks lead to both happy dogs and people.

Ageing isn't just physical. Keeping your dog's mind active is also helpful. Contrary to the popular adage, you can teach old dogs new tricks and you might just keep their brain and body younger as a result.

Even when physical activity might be limited, explore alternative low-impact games and pursuits, such as scentwork that you and your dog can do together. Using their nose is an inherently rewarding and fun thing for dogs to do, so training dogs to find items by scent will exercise them both mentally and physically.

Other exercise such as hydrotherapy a type of swimming exercise might be a good option especially for dogs who have conditions which affect their ability to exercise as normal.

Like many companion animals, dogs develop a clear attachment to their caregivers. The human-dog bond likely provides companionship and often, dog lovers describe them as a family member.

A stable caregiver-dog bond can help maintain a happy and mutually beneficial partnership between you and your dog. It can also help you recognize subtle changes in your dog's behavior or movement that might signal potential concerns.

Where there is compatibility between caregiver and dog, this leads to a better relationship and even benefits for owners, too, including stress relief and exercise. Sharing positive, fun experiences with your dog, including playing with them, are great for cementing your bond.

Modern veterinary medicine has seen substantial improvements in preventing and managing health concerns in dogs. Successful vaccination and parasite management programs have effectively reduced the incidence of disease in both dogs and humans including toxocariasis, which can be transmitted from dog feces to humans, and rabies, which can be transmitted dog-to-dog or dog-to-human.

Having a good relationship with your vet will allow you to tailor treatments and discuss your dog's needs. Regular health checks can also be useful in identifying any potential problems at a treatable stage such as dental issues or osteoarthritis which can cause pain and negatively impact the dog's wellbeing.

At the end of the day, it's a combination of our dog's genetics and the environment they live in that impacts their longevity. So while we can't change their genetics, there are many things we can do to improve their health that may just help them live a longer, healthier life.

Jacqueline Boyd, Senior Lecturer in Animal Science, Nottingham Trent University.

This article is republished from The Conversation under a Creative Commons license. Read the original article.

Follow this link:
Animal Expert Shares 5 Things That Will Help Your Dog Live a Longer, Healthier Life - ScienceAlert

Read More...

The Bat Elixir: Geneticists Suspect that the Flying Mammal Holds the Key to Extended Healthy Life | The Weather Channel – Articles from The Weather…

August 30th, 2021 1:55 am

A bat in flight.

Bats have developed a pretty bad rap sheet in the last few years. First, pop culture painted these mammals as a form of the blood-sucking Dracula, and then they were villainised for allegedly triggering a pandemic. Indeed, these poor creatures can't seem to catch a break! Aside from being adorable, bats have several other redeeming qualities like being the only mammals capable of flying and finding food even in complete darkness.

Of late, experts in genetics have uncovered a few startling facts about these Chiropterans, which could imply that they may hold the secret to healthy ageing. With the COVID-19 pandemic turning the spotlight on bats, their unique ability to stay alive against unmatched odds has also come under scrutiny.

The relationship between the size of a mammal, its metabolism, and lifespan is relatively straightforward. The larger the mammal, the slower its metabolism is, and this means a longer lifespan. While we humans ourselves are an exception to this rule, these flying mammals also deviate from this trend.

Some bats are known to live for 40 yearsthat's eight times longer than the lifespan of other animals their size! This unusually long lifespan of bats has always aroused the curiosity of scientistsit prompted them to ask the question, what was it that made these bats live longer?

The gene expression pattern in bats is very unique and has been associated with DNA repair, autophagy, immunity and tumour suppression, ensuring an extended health span for bats. Now, scientists are wondering if we could replicate a few such attributes on humans as well!

There's a cap-like structure called the telomere present at the end of each chromosomea microscopic threadlike part of the cell that carries part or all of the genetic material. This unique structure protects your chromosomes from damage. Every time your cells replicate, the chromosome loses just a little bit of the telomere. As time passes, this telomere gets very short, and either rides the wave of ageing or causes the cell to self-destruct. To put it succinctly, the shortening of your telomeres is why you age.

While this seems inevitable, studies conducted in the last few years revealed that the telomeres do not shorten in long-lived species of batslike the Myotis genus. This means that these species can protect their DNA for an unusually long-time in their lifespan.

A bat pup.

It's common knowledge that in humans, the body's ability to heal and repair any damage decreases considerably as we age. But researchers studied the genome of young, middle-aged, and old bats and found that their ability to repair DNA and damage caused by age increased as they grew older.

Another quality that contributes to their longevity is their ability to control their immune responses. With an over-excited immune response, humans tend to succumb to infections like COVID-19 quicker. In COVID-19 patients with regulated immune responses, the risk of ending up on the ventilator is much lower, reveals research.

Similarly, a controlled immune response could be why bats are able to carry numerous deadly pathogens like the coronavirus without succumbing to them easily.

Humans and bats have many similar genes but with a tweak here and a nip there. So, if we could someday discover what factors elicit these controlled immune responses and telomere shortening avoidance in bats and replicate it in humans, it would be a massive leap towards the utopian dream of a healthy, long life!

**

For weather, science, and COVID-19 updates on the go, download The Weather Channel App (on Android and iOS store). It's free!

See original here:
The Bat Elixir: Geneticists Suspect that the Flying Mammal Holds the Key to Extended Healthy Life | The Weather Channel - Articles from The Weather...

Read More...

Greenland Sharks Live Hundreds of Years; Can These Sharks Teach Humans How to Live Long? – Science Times

August 30th, 2021 1:55 am

A fishing expedition 15 years ago off the west coast of Greenland led scientists to discover the world's oldest vertebrate, Greenland sharks. This species can live at least 250 years. Scientists see lifestyle and genetics as a possible cause, and gene therapy techniques help humans adopt the same longevity.

Danish marine biologist John Steffensen was on a fishing expedition 15 years ago when he spotted an unusual-looking shark that hung from the boat's edge. Greenland sharks are large, sluggish, and awkwardly proportioned sharks that roam the icy depths of the North Atlantic Ocean and the Gulf of Mexico.

Steffensen and his colleagues published their findings in a study titled "Eye Lens Radiocarbon Reveals Centuries of Longevity in the Greenland Shark(Somniosus microcephalus)," onSciencein 2016. Since then, this cadaverous shark has become a sensation, with scientists worldwide trying to unlock the secret of its longevity, noting that it could show humans how to live long.

(Photo: Wikimedia Commons)Close-up image of a Greenland shark taken at the floe edge of the Admiralty Inlet, Nunavut

According toAtlas Obscura, Greenland sharks were commercially hunted for their oil-rich livers during the first half of the 20th century. However, presently, fishers find them a nuisance since these species feed o valuable halibut. Sometimes, they also get tangled with fishnets that could damage equipment on deck if they could not find a way out.

Steffensen's interest in Greenland sharks peaked when he learned of the extreme longevity of the sharks. They tried scanning the sharks for signs of growth rings but failed and found no evidence of their age.

So, he consulted retired physicist Jan Heinemeier from Denmark's Aarhus University, who gave him the idea of dating eye lenses produced at birth and could be subjected to carbon dating.

The results were astounding, showing that Greenland sharks could live at least 272 years up to 512 years old. In thevideoby Wonder World, they discussed that the oldest Greenland shark was 512 years old found in the North Atlantic, which could also hold the record of being the oldest living vertebrate in the world.

The scientists at first could not believe their findings, questioning whether they have made a mistake or not. Another thing they observed is that older Greenland sharks grow at a slower rate than young ones. The largest they found was 16 feet long, but they could still grow up to 18 feet.

ALSO READ: Two Female Sharks Reproduce Offspring; Recorded as First Case of Asexual Reproduction in Italy

Finding out that there could be sharks swimming in the ocean born during the Renaissance period is extraordinary. Scientists have asked how these creatures could live that long. They believe it might be due to genetics and lifestyle.

According toNBC News, Greenland sharks' longevity might have to do with their extraordinary heart and unique immune systems. The sharks' hearts pump slowly by about one beat per 12 seconds, and they have been beating already for centuries. On the other hand, a human heart beats about once every second and gradually slows down as humans age.

Moreover, DNA sequencing of Greenland sharks shows that genetic mutations in them have given them an immune system that can stop cancer and other infectious diseases.

In the future, scientists hope to transplant the genes to humans to promote long life using gene therapy techniques. However, this technology is in its early years, and more studies are needed to be successful.

RELATED ARTICLE: Godzilla Shark From 300 Million Years Ago Finally Gets New Name, Classified as New Species

Check out more news and information on Sharksin Science Times.

Go here to see the original:
Greenland Sharks Live Hundreds of Years; Can These Sharks Teach Humans How to Live Long? - Science Times

Read More...

9 Healthy Eating Habits to Live Over A Century, Say Dietitians | Eat This Not That – Eat This, Not That

August 30th, 2021 1:55 am

You don't have to live in a blue zone to live over a century. "Blue zones" are known to have the densest population of people that live to be over 100located in five different communities around the world. And yet, while these communities are known for being the healthiest and living the longest, the truth is, you don't have to be a community member to reap the same benefits. While genetics do play a role in longevity, setting healthier habits also significantly increases your chances of living long enough to reach that three-digit number.

So what's their secret? If you were to place a microscope on these communities, you would notice that their diets include a variety of real, whole foods. They also focus on eating at the table, sharing meals with others, and regularly moving their bodies.

But what's exactly on their plates? We spoke with a few registered dietitians to look at some of the healthy eating habits that can help you to live over a century, and these tips line up closely with the type of lifestyles lived by those in blue zones. Here are the healthy eating habits you can incorporate into your life today in order to have a happier, healthier tomorrow. Then, be sure to check out our list of The 7 Healthiest Foods to Eat Right Now.

"It is well-known that fruit and vegetables are good for you, but it's important to remember that it's more than just that," says Amy Goodson, MS, RD, CSSD, LD. "Colorful fruits and veggies provide the body with various vitamins, minerals, antioxidants, and plant compounds that help the heart, the gut as well as keep your immune system strong and more! Each color of produce contains a different nutrient package."

RELATED:Get even more healthy eating tips straight to your inbox by signing up for our newsletter!

"While everyone's body and natural genetics are different, fueling your body appropriately is a crucial component if you would like to live over a century," says Ricci-Lee Hotz, MS, RDN at A Taste of Health, LLC and Expert at Testing.com. "Ensuring that you consume a varied diet with a range of different fruits, veggies, lean proteins, whole grain, high fiber carbs, and healthy fat, and balancing them appropriately at each meal and snack is crucial to make sure your body is getting everything it needs to function at its best. In addition, keeping your stress levels down (especially surrounding food) can always help your body stay as healthy as possible, too."

"Following a plant-based diet is one of the best possible dietary choices to live a life with greater quality and quantity," says Trista Best, MPH, RD, LD, and a registered dietitian at Balance One Supplements. "For many who turn to a plant-based diet, their goal is overall health and reduced risk of chronic disease, which culminates in longer life. Among the many benefits of a plant-based diet, including, heart health, weight loss, and diabetes prevention a new secondary benefit is emerging; reduced cancer risk."

Best points out research from the American Institute for Cancer Research which states that one of the best ways to prevent cancer is through dietary means. Focusing on nutrients like fiber, vitamins, minerals, and phytonutrients into your diet is key, and can be found in foods like vegetables, fruit, beans, grains, nuts, and seeds.

If going plant-based does not feel like something that is attainable for you, Best also recommends focusing on a flexitarian approach if you want to live over a century.

"For many, this can be a daunting task and a flexitarian approach may be the best option," she says. "Regardless of where you fall, reducing animal protein in your diet will improve your longevity."

Here are 10 Benefits of Eating a More Plant-Based Diet.

"The healthiest of people fill their plate with nutrient-rich foods like whole grains, fruits, vegetables, lean protein, dairy, and healthy fat, but they also allow for pleasure foods," says Goodson. "The key to a long, happy life is balance. The majority of the time, 80%, eat foods to fuel your body and keep it strong. Then 20% of the time enjoy vacations, holidays, and desserts with the people you love. It's the best plan for the body and the soul."

It's all about setting healthier habits for yourself! Here are5 Healthy Dessert Habits For A Flat Belly.

"It's important to not overeat," Rachel Paul, PhD, RD from CollegeNutritionist.com. "Overeating calories, even of healthier foods, leads to weight gain. Those with overweight or obese bodies are more likely to develop diseases such as diabetes, heart disease, and some cancers, which can lead to premature death."

One of the best ways to combat overeating is to start paying attention to your body's hunger and fullness clues, portioning out your meals, and setting specific times for meals and snacks throughout the day. Overeating and mindless snacking can easily come hand-in-hand, so it's important to set healthy snacking habits that will help you feel full, prevent overeating, and help you ultimately live over a century.

"As we age, we typically lose 2 to 3% muscle mass per decade," says Goodson. "That can lead to falls, bone breaks, and instability as we age. The key? Power up with lean protein at all meals and snacks. Protein helps and builds and repairs muscles helping to keep your body strong as you age. Including foods like lean beef, poultry, fish, eggs, dairy, beans, and legumes can all help you amp up your protein."

"As a dietitian, I'm always telling people to 'eat the rainbow' because all the different colored foods represent different phytonutrients that help keep us healthy as we age," says Mackenzie Burgess, RDN and recipe developer at Cheerful Choices. "One beneficial type of phytonutrient you'll find in colorful fruits, vegetables, and other plant foods are compounds called 'flavonoids.' In fact, recent research has proven these flavonoids to be helping in maintaining our brain health long-term. Flavonoid-rich foods include onions, berries, dark greens, herbs, broccoli, cauliflower, dark chocolate, soy, and citrus fruits."

To easily incorporate flavonoid-rich foods into your diet, Burgess says "For breakfast try mashing together berries and chia seeds to make your own jam. Then, for lunch, blend cauliflower into rice or find it in flatbread form to pair with your favorite protein. Finally, for dinner, try stirring extra onions and herbs into a one-pot curry."

"To keep our brains sharp and to prevent cognitive decline, what we eat can make a difference," says Lisa R. Young, PhD, RDN, author of Finally Full, Finally Slim and a member of our medical expert board. "Foods high in certain vitamins, antioxidants, and phytochemicals may help to boost brain health. Deep red foods such as tomatoes and watermelon contain the antioxidant lycopene which fights free radicals that come with aging. Leafy greens such as kale and spinach are rich in vitamins E and K which may prevent memory loss and help reduce our 'brain age.'"

Related:Why You Need Antioxidants In Your DietAnd How To Eat More Of Them

"As we age, our metabolism tends to slow down so it is important to watch calories and exercise more to avoid weight gain," says Young. "It turns out that maintaining a steady weight and avoiding yo-yo dieting is equally important. The centenarians from Okinawa, known to live long and healthy lives, were known to keep their calories down and their weight steady. Maintaining a healthy body mass index (BMI) has been associated with lower rates of heart disease and certain cancers."

For more, be sure to read our list of The 6 Best Diets That Will Make You Live Longer, Say Dietitians.

Link:
9 Healthy Eating Habits to Live Over A Century, Say Dietitians | Eat This Not That - Eat This, Not That

Read More...

Dad with multiple sclerosis who fought for treatment in Panama during Covid restrictions finds first round is ‘reaping rewards’ – South West Londoner

August 30th, 2021 1:54 am

A former junior motorsport racer with multiple sclerosis who battled against the odds to receive experimental stem cell treatment in Panama in April is already noticing improvements in his condition.

Alister Bailey, 39, a former Barnes resident, travelled to the Stem Cell Institute with his wife Gemma, despite warnings they would not be let in to Panama due to coronavirus travel restrictions.

MS is an autoimmune disease that can affect the brain and spinal cord. Common symptoms include mobility problems, vision problems, muscle spasms, fatigue and speech difficulties.

Before Panama, Alister couldnt hold a cup of tea, but now his hands have stopped shaking and he can pour a drink without spilling it. He has also noticed an improvement in his eyesight.

Gemma said: This might seem trivial but its a huge physical change.Thats a really positive sign and certainly encouraging for us in terms of the next round.

We have seen some positive signs already which is amazing because we didnt really have any expectations this time round to be honest; it was more to stop the deterioration.

He really believes it will work and he feels something is happening.

The Baileys are currently fundraising to get Alister back to Panama for a second round of treatment in November.

The pair were supposed to fly out to Panama for the first round in January after raising 22,500, but coronavirus put a stop to those plans.

Travel restrictions meant they had to delay the trip until the end of April but, even then, it was not an easy ride.

Read below about their rollercoaster journey:

The pair opted for experimental mesenchymal stem cell therapy because treatment options for progressive MS are limited.

A year after he married Gemma, Alister started experiencing episodes where he wasnt able to walk and then he went blind for two days in 2012.

Since receiving his diagnosis, Alister has been on a drug for ten years to slow symptom progression. But Gemma said his condition has rapidly deteriorated in the past three years. While he does not use a wheelchair at home, he cannot walk any long distance unsupported.

She said: Theres no cure for progressive MS so this treatment in Panama is his only hope.

Alister didnt qualify for anything on the NHS which was pretty disheartening.

We have various doctor friends, some of them researching stem cell treatments for different illnesses but they said this is where medicine is going in the future.

The Stem Cell Institute administers mesenchymal stem cells (MSCs) which are recovered from donated umbilical cords and grown in labs.

MSCs are adult cells which can produce other cells like muscle. This is why researchers are interested in testing whether they can protect nerves from more damage and repair the original damage.

The Baileys are hoping to see the best benefits of the treatment after two or three rounds and have prepared themselves for potentially five visits.

They have planned fundraising events to get together the funds needed for November.

On 17 July, Alisters 67-year-old dad Chris took on the Surrey Hills Epic Off-Road Challenge which involves 125km of off-road mountain biking.

Gemma is organising a charity dinner and her friend Claire is running the Lulworth Cove Trail Challenge which involves running along the coastline.

Their friend Jonny Wright has already raised $14,400 as he prepares to cycle 2,500 miles from Maine to Florida in 30 days starting on 27 August.

Their hope is that the treatment will stimulate repair of the damaged tissues so that Alister can play football with his son again.

You can follow the familys journey on their Instagram page.

You can donate to their fundraiser here.

Credit for all photos: Gemma and Alister Bailey.

See the original post here:
Dad with multiple sclerosis who fought for treatment in Panama during Covid restrictions finds first round is 'reaping rewards' - South West Londoner

Read More...

Multiple sclerosis and the experimental treatment giving families hope – South West Londoner

August 30th, 2021 1:54 am

Multiple sclerosis is an autoimmune disease that can affect the brain and spinal cord, and it is estimated that 130,000 people in the UK have the condition.

There are drugs available to slow the onset of symptoms but treatment options for progressive MS are limited and there is currently no cure.

At the end of July, the US Food and Drug Administration authorised a Phase 2 clinical trial at Hope Biosciences Stem Cell Research Foundation in Texas.

The future of MS treatment is exciting; scientists think solutions for all types of MS could be in their late stage trials by 2025.

But what are the options for those living with progressive MS right now? Some are desperate to halt their symptom deterioration.

Increasingly, they are looking to experimental treatments like the one offered by Panamas Stem Cell Institute.

Alister Bailey and Liam Egalton both raised tens of thousands of pounds to travel to Panama for mesenchymal stem cell therapy. To find out about their turbulent journeys during the pandemic and learn more about ongoing MS treatment research projects, read the full story here:

https://swlondoner.shorthandstories.com/multiple-sclerosis-and-the-experimental-treatment-giving-families-hope/index.html

Read more from the original source:
Multiple sclerosis and the experimental treatment giving families hope - South West Londoner

Read More...

Global Regenerative Medicine Market (2021 to 2030) – by Product, Material, Application and Region – ResearchAndMarkets.com – Business Wire

August 30th, 2021 1:52 am

DUBLIN--(BUSINESS WIRE)--The "Regenerative Medicine Market by Product, by Material, by Application - Global Opportunity Analysis and Industry Forecast, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market is expected to reach USD 172.15 billion by 2030 from USD 13.96 billion in 2020, at a CAGR of 28.9%.

Companies Mentioned

Regenerative Medicine are used to regenerate, repair, replace or restore tissues and organs damaged by diseases or due to natural ageing. These medicines help in the restoration of normal cell functions and are widely used to treat various degenerative disorders such as cardiovascular disorders, orthopedic disorders and others.

The rising demand for organ transplantation and increasing awareness about the use of regenerative medicinal therapies in organ transplantation along with implementation of the 21st Century Cures Act, a U.S. law enacted by the 114th United States Congress in December 2016 are creating growth opportunities in the market. However, high cost of treatment and stringent government regulations are expected to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and RoW.

Key Topics Covered:

1. Introduction

2. Regenerative Medicine Market - Executive Summary

3. Porter's Five Force Model Analysis

4. Market Overview

4.1. Market Definition and Scope

4.2. Market Dynamics

5. Global Regenerative Medicine Market, by Product Type

5.1. Overview

5.2. Cell Therapy

5.3. Gene Therapy

5.4. Tissue Engineering

5.5. Small Molecules & Biologics

6. Global Regenerative Medicine Market, by Material

6.1. Overview

6.2. Synthetic Materials

6.3. Biologically Derived Materials

6.4. Genetically Engineered Materials

6.5. Pharmaceuticals

7. Global Regenerative Medicine Market, by Application

7.1. Overview

7.2. Cardiovascular

7.3. Oncology

7.4. Dermatology

7.5. Musculoskeletal

7.6. Wound Healing

7.7. Opthalomolgy

7.8. Neurology

7.9. Others

8. Global Regenerative Medicine Market, by Region

8.1. Overview

8.2. North America

8.3. Europe

8.4. Asia-Pacific

8.5. Rest of World

9. Company Profile

9.1. Integra Lifesciences Corporation

9.2. Abbvie Inc.

9.3. Merck Kgaa

9.4. Medtronic plc

9.5. Thermo Fisher Scientific Inc.

9.6. Smith+Nephew

9.7. Becton, Dickinson and Company

9.8. Baxter International Inc

9.9. Cook Biotech

9.10. Organogenesis Inc

For more information about this report visit https://www.researchandmarkets.com/r/nzud5i

Read the original:
Global Regenerative Medicine Market (2021 to 2030) - by Product, Material, Application and Region - ResearchAndMarkets.com - Business Wire

Read More...

Global Cryopreservation Equipment Market Report 2021-2028 – Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking…

August 30th, 2021 1:52 am

DUBLIN--(BUSINESS WIRE)--The "Cryopreservation Equipment Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Type, Cryogen Type, Application, End User, and Geography" report has been added to ResearchAndMarkets.com's offering.

Freezers Segment to Contribute Major Share to Cryopreservation Equipment Market

Cryopreservation Equipment Market to reach US$ 11,255.02 million by 2028 from US$ 5,798.82 million in 2021; it is estimated to grow at a CAGR of 9.9%

The report highlights the trends prevailing in the market along with the market drivers and deterrents. The factors such as growing acceptance for regenerative medicine and increasing needs of biobanking practices drive the market growth. However, stringent regulatory requirements hinder the cryopreservation equipment market growth.

Cryopreservation plays an important part in the field of regenerative medicine as it facilitates stable and secure storage of cells and other related components for a prolonged time. Regenerative medicine enables replacing diseased or damaged cells, tissues, and organs by retrieving their normal function through stem cell therapy.

Owing to the advancements in the medical technology, stem cell therapy is now being considered as an alternative to traditional drug therapies in the treatment of a wide range of chronic diseases, including diabetes and neurodegenerative diseases.

Moreover, the US Food and Drug Administration (FDA) has approved blood-forming stem cells. The blood-forming stem cells are also known as hematopoietic progenitor cells that are derived from umbilical cord blood. The growing approvals for stem cell and gene therapies are eventually leading to the high demand for cryopreservation equipment. Following are a few instances of stem cell and gene therapies approved by the FDA and other regulatory bodies.

Based on type, the cryopreservation equipment market is segmented into freezers, sample preparation systems, and accessories. In 2020, the freezers segment held the largest share of the market, and it is expected to register the highest CAGR during 2021-2028. In ultracold freezers, liquid nitrogen is used for the successful preservation of more complex biological structures by virtually seizing all biological activities.

The COVID-19 pandemic has had a mixed impact on the cryopreservation equipment market. Restricted access to family planning services as well as diverted focus of people due to economic uncertainties and recession, and disturbed work-life balance have led to rise in egg and embryo freezing activities at fertility clinics during the pandemic.

As a result, the rising use of cryopreservation equipment is boosting the market growth. Furthermore, supply chain disruption caused due to congestion of ports and disturbances in other transport means has substantially affected the distribution of cryopreservation equipment and other accessories.

Market players are launching new and innovative products and services to maintain their position in the cryopreservation equipment market. In May 2021, Stirling Ultracold has been acquired by BioLife Solutions, Inc for cell and gene therapies and the broader biopharma market. In return for all of Stirling's outstanding shares, BioLife issued 6,646,870 shares of ordinary stock.

Key Market Dynamics

Market Drivers

Market Restraints

Market Opportunities

Future Trends

The report segments the global cryopreservation equipment market as follows:

By Type

By Cryogen Type

By Application

By End User

Companies Mentioned

For more information about this report visit https://www.researchandmarkets.com/r/tjgti5

Read the original post:
Global Cryopreservation Equipment Market Report 2021-2028 - Growing Acceptance for Regenerative Medicine & Increasing Needs of Biobanking...

Read More...

Worldwide Regenerative Medicine Industry to 2030 – Featuring AbbVie, Medtronic and Thermo Fisher Scientific Among Others – GlobeNewswire

August 30th, 2021 1:52 am

Dublin, Aug. 27, 2021 (GLOBE NEWSWIRE) -- The "Regenerative Medicine Market by Product, by Material, by Application - Global Opportunity Analysis and Industry Forecast, 2021 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global regenerative medicine market is expected to reach USD 172.15 billion by 2030 from USD 13.96 billion in 2020, at a CAGR of 28.9%. Regenerative Medicine are used to regenerate, repair, replace or restore tissues and organs damaged by diseases or due to natural ageing. These medicines help in the restoration of normal cell functions and are widely used to treat various degenerative disorders such as cardiovascular disorders, orthopedic disorders and others.

The rising demand for organ transplantation and increasing awareness about the use of regenerative medicinal therapies in organ transplantation along with implementation of the 21st Century Cures Act, a U.S. law enacted by the 114th United States Congress in December 2016 are creating growth opportunities in the market. However, high cost of treatment and stringent government regulations are expected to hinder the market growth.

The global regenerative medicine market is segmented based on product type, material, application, and geography. Based on product type, the market is classified into cell therapy, gene therapy, tissue engineering, and small molecule & biologic. Depending on material, it is categorized into synthetic material, biologically derived material, genetically engineered material, and pharmaceutical. Synthetic material is further divided into biodegradable synthetic polymer, scaffold, artificial vascular graft material, and hydrogel material. Biologically derived material is further bifurcated into collagen and xenogenic material. Genetically engineered material is further segmented into deoxyribonucleic acid, transfection vector, genetically manipulated cell, three-dimensional polymer technology, transgenic, fibroblast, neural stem cell, and gene-activated matrices. Pharmaceutical is further divided into small molecule and biologic. By application, it is categorized into cardiovascular, oncology, dermatology, musculoskeletal, wound healing, ophthalmology, neurology, and others. Geographically, it is analyzed across four regions, i.e., North America, Europe, Asia-Pacific, and RoW.

The key players operating in the global regenerative medicine market include Integra Lifesciences Corporation, AbbVie Inc., Merck KGaA, Medtronic, Thermo Fisher Scientific Inc., Smith+Nephew, Becton, Dickinson and Company, Baxter International Inc, Cook Biotech, and Organogenesis Inc., among others.

Key Topics Covered:

1. Introduction

2. Regenerative Medicine Market - Executive Summary

3. Porter's Five Force Model Analysis

4. Market Overview4.1. Market Definition and Scope4.2. Market Dynamics

5. Global Regenerative Medicine Market, by Product Type5.1. Overview5.2. Cell Therapy5.3. Gene Therapy5.4. Tissue Engineering5.5. Small Molecules & Biologics

6. Global Regenerative Medicine Market, by Material6.1. Overview6.2. Synthetic Materials6.3. Biologically Derived Materials6.4. Genetically Engineered Materials6.5. Pharmaceuticals

7. Global Regenerative Medicine Market, by Application7.1. Overview7.2. Cardiovascular7.3. Oncology7.4. Dermatology7.5. Musculoskeletal7.6. Wound Healing7.7. Opthalomolgy7.8. Neurology7.9. Others

8. Global Regenerative Medicine Market, by Region8.1. Overview8.2. North America8.3. Europe8.4. Asia-Pacific8.5. Rest of World

9. Company Profile9.1. Integra Lifesciences Corporation9.2. Abbvie Inc.9.3. Merck Kgaa9.4. Medtronic plc9.5. Thermo Fisher Scientific Inc.9.6. Smith+Nephew9.7. Becton, Dickinson and Company9.8. Baxter International Inc9.9. Cook Biotech9.10. Organogenesis Inc

For more information about this report visit https://www.researchandmarkets.com/r/pl6r1p

See the original post:
Worldwide Regenerative Medicine Industry to 2030 - Featuring AbbVie, Medtronic and Thermo Fisher Scientific Among Others - GlobeNewswire

Read More...

2 surgeons weigh in on the most promising areas of regenerative medicine – Becker’s Orthopedic & Spine

August 30th, 2021 1:52 am

Regenerative medicine is a growing area of orthopedic treatment. Two orthopedic surgeons told Becker's what they found the most exciting about its development.

Ask Orthopedic Surgeons is a weekly series of questions posed to orthopedic surgeons around the country about clinical, business and policy issues affecting orthopedic care. We invite all orthopedic surgeon and specialist responses.

Next week's question: How will joint replacement surgical robots improve in the next 10 years?

Please send responses to Carly Behm at cbehm@beckershealthcare.com by 5 p.m. CDT Tuesday, Aug. 31.

Note: Responses were edited for style.

Question: What area of regenerative medicine holds the most promise for orthopedics?

Mihir Patel, MD. OrthoIndy (Indianapolis): Regenerative medicine is a truly exciting frontier in medicine. In orthopedics, bone graft implants and substitutes are helping patients return to normal activities. The implants can be used in index operations as well as revisions for a variety of orthopedic procedures including acute stress reactions, stress fractures not conducive to metal fixation, and subchondral procedures. The evolution of orthopedic implants from metal to plastic, and now bone is improving outcomes for patients and broadening our arsenal as surgeons to help patients heal. The bone graft substitutes are reducing comorbidities of graft harvesting. Additionally, they are adding to the value proposition for patients who may have difficulty healing bone defects, nonunions, and osteoporosis.

Much like advances in cancer therapies over the past decade, bone graft substitutes have the potential for personalized, targeted medicine for these diagnoses as biomarkers become more available to help clinicians really pinpoint at the molecular level why some heal more quickly than others. Finally, regenerative medicine includes mostly outpatient procedures with sterile kits that are easily transported, giving orthopedic surgeons the confidence in the manufacturing and sterilization process.

Jason Snibbe, MD. Snibbe Orthopedics (Los Angeles): I think the use of biologics from plasma and bone marrow have the most promise right now to help a variety of injuries in orthopedics. We are able to help people recover without surgery and use their own tissue to heal, specifically in labral tears of the hip and meniscus tears in the knee.

Read more from the original source:
2 surgeons weigh in on the most promising areas of regenerative medicine - Becker's Orthopedic & Spine

Read More...

UC Davis and the School of Medicine set new records in research funding – UC Davis Health

August 30th, 2021 1:52 am

The University of California, Davis, set a new record for external research funding, receiving $968 million in awards in the fiscal year 2020-21, up $27 million from the previous record set last year. A major reason for this years growth was increased funding related to medicine and public health.

Professors Diana Farmer and Aijun Wang are collaborating to develop a stem cell treatment for spina bifida. (2019)

The School of Medicine received the largest increase in funding, up $92 million from the previous year, for a total of $368 million. Funding related to COVID-19 research totaled $42 million for the year. Studies in this area are providing critical insight into testing, vaccines, treatments and social impacts.

We are very proud of our researchers at the School of Medicine who rose to the challenge and expanded their groundbreaking work in the face of the pandemic, said Allison Brashear, dean of the UC Davis School of Medicine. All our research teams have shown great agility and collaboration across disciplines, quickly responding to emerging needs to prevent transmission and find treatments and vaccines to combat COVID-19, while also offering patients life-saving clinical trials in areas involving stem cell treatments, cancer and neuroscience, among many others.

Brashear noted that the School of Medicines clinical trials grew by 63% in the last year to $98 million.

The College of Agricultural and Environmental Sciences ($153 million), School of Veterinary Medicine ($83 million), College of Engineering ($80 million) and College of Biological Sciences ($58 million) rounded out the top five recipients.

This achievement reflects the unwavering commitment of our research community and their passion to address important societal needs during a year when operations were constrained due to the COVID-19 pandemic, Chancellor Gary S. May said. The societal impact of UC Davis research is far-reaching, spanning geographical boundaries and catering to diverse populations and needs.

The awards enable a broad range of research on topics including advancing human and animal health, protecting our planet and food supply and enabling a more resilient society.

The largest award, $51 million from the Department of Health and Human Services Centers for Disease Control and Prevention, went to Marc Schenker, distinguished professor of Public Health Sciences, to improve public health outcomes for all Californians by providing proper disease surveillance and prevention.

The federal government remains the largest provider of funding at $514 million, up $37 million from last year. The second leading source came from the state of California at $164 million, up $32 million. Funding from industry made up the third highest source, totaling $116 million, up $31 million.

UC Davis researchers received a total of 18 NSF CAREER Awards, a record for the university. These prestigious grants are offered to early-career faculty who have the potential to serve as academic role models in research and education and to lead advances in the mission of their department or organization.

Collaborative research bringing experts together from different fields of study continues to attract significant funding. These joint efforts often focus on addressing complex, large-scale challenges that require expertise from many perspectives.

We continue to see how multidisciplinary research provides a distinct advantage in tackling multifaceted issues, said Prasant Mohapatra, vice chancellor for Research at UC Davis. As one of the most academically comprehensive universities in the world, UC Davis offers a unique environment to solve these complex issues by bringing together experts from across our campuses.

Notable multidisciplinary awards include a $16 million grant from the National Institute of Mental Health for the UC Davis Conte Center to explore how infections in pregnancy lead to disorders in offspring. Principal investigators on this grant are Kimberly McAllister and Cameron Carter.

The Interdisciplinary Research and Strategic Initiatives division within the Office of Research offers support and resources to help teams advance their programs. Some of the notable interdisciplinary research projects include the work of Sheryl Catz, professor at the UC Davis Betty Irene Moore School of Nursing. Catz received $225,000 from the NIH National Cancer Institute for a project to improve the reach and effectiveness of smoking cessation services targeted to veterans living with HIV.

Diana Farmer, professor and chair in the Department of Surgery at UC Davis Health, also received $9 million from the California Institute for Regenerative Medicine (CIRM). Farmer is the principal investigator of the clinical trial, known formally as The CuRe Trial a cellular therapyfor in utero repair of myelomeningocele which uses stem cells before birth to treat the most serious form of spina bifida.

This story was originally written by Neelanjana Gautam and published here.

Note: Where funds are awarded up-front to cover several years, the money is counted in the first year the award was received. Incrementally funded awards are counted as authorized in each year. Reports are based on the principal investigators home school or college.

See more here:
UC Davis and the School of Medicine set new records in research funding - UC Davis Health

Read More...

These 4 tech breakthroughs could help end aging – Fast Company

August 30th, 2021 1:52 am

We live in a unique time when for the first time in human history there is a real opportunity to extend our lives dramatically. Recent scientific discoveries and technological breakthroughs that soon will translate into affordable and accessible life-extending tools will let us break the sound barrier of the current known record of 122 years. I am talking about breakthroughs in genetic engineering, regenerative medicine, healthcare hardware, and health data.

Very soon, slowing, reversing, or even ending aging will become a universally accepted ambition within the healthcare community. Technology is converging to make this a certainty. Developments in the understanding and manipulation of our genes and cells, in the development of small-scale health diagnostics, and in the leveraging of data for everything from drug discovery to precision treatment of disease are radically changing how we think about healthcare and aging.

When I speak of the Longevity Revolution, what I really mean is the cumulative effect of multiple breakthroughs currently underway across several fields of science and technology. Together, these parallel developments are forming the beginning of a hockey-stick growth curve that will deliver world-changing outcomes.

Completed in 2003, the Human Genome Project successfully sequenced the entire human genomeall 3 billion nucleotide base pairs representing some 25,000 individual genes. The project, arguably one of the most ambitious scientific undertakings in history, cost billions of dollars and took 13 years to complete. Today, your own genome can be sequenced in as little time as a single afternoon, at a laboratory cost of as little as $200.

The consequences of this feat are nothing short of revolutionary. Gene sequencing allows us to predict many hereditary diseases and the probability of getting cancer. This early benefit of gene sequencing became widely known when Angelina Jolie famously had a preventative double mastectomy after her personal genome sequencing indicated a high vulnerability to breast cancer. Genome sequencing helps scientists and doctors understand and develop treatments for scores of common and rare diseases. Along with advances in artificial intelligence, it helps determine medical treatments precisely tailored to the individual patient.

Longevity scientists have even identified a number of so-called longevity genes that can promise long and healthy lives to those who possess them. Scientists now understand far better than ever before the relationship between genes and aging. And while our genes do not significantly change from birth to death, our epigenomethe system of chemical modifications around our genes that determine how our genes are expresseddoes. The date on your birth certificate, it turns out, is but a single way to determine age. The biological age of your epigenome, many longevity scientists now believe, is far more important.

Best of all, however, science is beginning to offer ways to alter both your genome and epigenome for a healthier, longer life. New technologies like CRISPR-Cas9 and other gene-editing tools are empowering doctors with the extraordinary ability to actually insert, delete, or alter an individuals genes. In the not terribly distant future, we will be able to remove or suppress genes responsible for diseases and insert or amplify genes responsible for long life and health.

Gene editing is just one of the emerging technologies of the genetic revolution: Gene therapy works by effectively providing cells with genes that produce necessary proteins in patients whose own genes cannot produce them. This process is already being applied to a few rare diseases, but it will soon become a common and incredibly effective medical approach. The FDA expects to approve 10 to 20 such therapies by the year 2025.

Another major transformation driving the Longevity Revolution is the field of regenerative medicine. During aging, the bodys systems and tissues break down, as does the bodys ability to repair and replenish itself. For that reason, even those who live very long and healthy lives ultimately succumb to heart failure, immune system decline, muscle atrophy, and other degenerative conditions. In order to achieve our ambition of living to 200, we need a way to restore the body in the same way we repair a car or refurbish a home.

Several promising technologies are now pointing the way to doing just that. While it is still quite early, there are already a few FDA-approved stem cell therapies in the United States targeting very specific conditions. Stem cellscells whose job it is to generate all the cells, tissues, and organs of your bodygradually lose their ability to create new cells as we age. But new therapies, using patients own stem cells, are working to extend the bodys ability to regenerate itself. These therapies hold promise for preserving our vision, cardiac function, joint flexibility, and kidney and liver health; they can also be used to repair spinal injuries and help treat a range of conditions from diabetes to Alzheimers disease. The FDA has approved 10 stem cell treatments, with more likely on the way.

Its one thing to replenish or restore existing tissues and organs using stem cells, but how about growing entirely new organs? As futuristic as that sounds, it is already beginning to happen. Millions of people around the world who are waiting for a new heart, kidney, lung, pancreas, or liver will soon have their own replacement organs made to order through 3D bio-printing, internal bioreactors, or new methods of xenotransplantation, such as using collagen scaffoldings from pig lungs and hearts that are populated with the recipients own human cells.

Even if this generation of new biological organs fails, mechanical solutions will not. Modern bioengineering has successfully restored lost vision and hearing in humans using computer sensors and electrode arrays that send visual and auditory information directly to the brain. A prosthetic arm developed at Johns Hopkins is one of a number of mechanical limbs that not only closely replicate the strength and dexterity of a real arm but also can be controlled directly by the wearers mindjust by thinking about the desired movement. Today, mechanical exoskeletons allow paraplegics to run marathons, while artificial kidneys and mechanical hearts let those with organ failure live on for years beyond what was ever previously thought possible!

The third development underpinning the Longevity Revolution will look more familiar to most: connected devices. You are perhaps already familiar with common wearable health-monitoring devices like the Fitbit, Apple Watch, and ura Ring. These devices empower users to quickly obtain data on ones own health. At the moment, most of these insights are relatively trivial. But the world of small-scale health diagnostics is advancing rapidly. Very soon, wearable, portable, and embeddable devices will radically reduce premature death from diseases like cancer and cardiovascular disease, and in doing so, add years, if not decades, to global life expectancy.

[Photo: BenBella Books]The key to this part of the revolution is early diagnosis. Of the nearly 60 million lives lost around the globe each year, more than 30 million are attributed to conditions that are reversible if caught early. Most of those are noncommunicable diseases like coronary heart disease, stroke, and chronic obstructive pulmonary disease (bronchitis and emphysema). At the moment, once you have gone for your yearly physical exams, stopped smoking, started eating healthy, and refrained from having unprotected sex, avoiding life-threatening disease is a matter that is largely out of your hands. We live in a world of reactive medicine. Most people do not have advanced batteries of diagnostic tests unless theyre experiencing problems. And for a large percentage of the worlds population, who live in poor, rural, and remote areas with little to no access to diagnostic resources, early diagnosis of medical conditions simply isnt an option.

But not for long. Soon, healthcare will move from being reactive to being proactive. The key to this shift will be low-cost, ubiquitous, connected devices that constantly monitor your health. While some of these devices will remain external or wearable, others will be embedded under your skin, swallowed with your breakfast, or remain swimming through your bloodstream at all times. They will constantly monitor your heart rate, your respiration, your temperature, your skin secretions, the contents of your urine and feces, free-floating DNA in your blood that may indicate cancer or other disease, and even the organic contents of your breath. These devices will be connected to each other, to apps that you and your healthcare provider can monitor, and to massive global databases of health knowledge. Before any type of disease has a chance to take a foothold within your body, this armory of diagnostic devices will identify exactly what is going on and provide a precise, custom-made remedy that is ideal just for you.

As a result, the chance of your disease being diagnosed early will become radically unshackled from the limitations of cost, convenience, and medical knowledge. The condition of your body will be maintained as immaculately as a five-star hotel, and almost nobody will die prematurely of preventable disease.

There is one final seismic shift underpinning the Longevity Revolution, and its a real game-changer. Pouring forth from all of these digital diagnostic devices, together with conventional medical records and digitized research results, is a torrent of data so large it is hard for the human mind to even fathom it. This data will soon become grist for the mill of powerful artificial intelligence that will radically reshape every aspect of healthcare as we know it.

Take drug discovery, for instance. In the present day, it takes about 12 years and $2 billion to develop a new pharmaceutical. Researchers must painstakingly test various organic and chemical substances, in myriad combinations, to try to determine the material candidates that have the best chance of executing the desired medical effect. The drugs must be considered for the widest range of possible disease presentations, genetic makeup, and diets of targeted patients, side effects, and drug interactions. There are so many variables that it is little short of miraculous that our scientists have done so much in the field of pharmaceutical development on their own. But developing drugs and obtaining regulatory approval is a long and cash-intensive process. The result is expensive drugs that largely ignore rarer conditions.

AI and data change that reality. Computer models now look at massive databases of patient genes, symptoms, disease species, and millions of eligible compounds to quickly determine which material candidates have the greatest chance of success, for which conditions, and according to what dose and administration. In addition to major investments by Big Pharma, there are currently hundreds of startups working to implement the use of AI to radically reshape drug discovery, just as we saw happen in the race to develop COVID-19 vaccines. The impact that this use of AI and data will have on treating or even eliminating life-threatening diseases cannot be overstated.

But that is not the only way that artificial intelligence is set to disrupt healthcare and help set the Longevity Revolution in motion. It will also form the foundation of precision medicinethe practice of custom-tailoring health treatments to the specific, personal characteristics of the individual.

Today, healthcare largely follows a one-size-fits-all practice. But each of us has a very unique set of personal characteristics, including our genes, microbiome, blood type, age, gender, size, and so on. AI will soon be able to access and analyze enormous aggregations of patient data pulled together from medical records, personal diagnostic devices, research studies, and other sources to deliver highly accurate predictions, diagnoses, and treatments, custom-tailored to the individual. As a result, healthcare will increasingly penetrate remote areas, becoming accessible to billions of people who today lack adequate access to medical care.

I predict that the development of AI in healthcare will change how we live longer, healthier lives as radically as the introduction of personal computers and the internet changed how we work, shop, and interact. Artificial intelligence will eliminate misdiagnosis; detect cancer, blood disease, diabetes, and other killers as early as possible; radically accelerate researchers understanding of aging and disease; and reestablish doctors as holistic care providers who actually have time for their patients. In as little as 10 years time, we will look back at the treatment of aging and disease today as quite naive.

The Longevity Revolution lives not in the realm of science fiction but in the reality of academic research laboratories and commercial technology R&D centers. The idea of aging as a fixed and immutable quality of life that we have no influence upon is ready to be tossed into the dustbin of history.

Sergey Young is a renowned VC, longevity visionary, and founder of the $100 million Longevity Vision Fund. This is an adapted excerpt from The Science and Technology of Growing Young, with permission by BenBella Books.

View original post here:
These 4 tech breakthroughs could help end aging - Fast Company

Read More...

Human Embryonic Stem Cells (HESC) Market Updates to 2021: Brief, Trends, Applications, Types, Research, Forecast to 2028 UNLV The Rebel Yell – UNLV…

August 30th, 2021 1:52 am

The global Human Embryonic Stem Cells (HESC) Market has been comprehensively analyzed and the results are presented in the market report published. The market concentration that is currently occupied by the Human Embryonic Stem Cells (HESC) market and an overview of the Human Embryonic Stem Cells (HESC) manufacturing industry is extensively researched in the report. An analysis of the collected data is used to reveal the market revenue earned by the different companies operating in the Human Embryonic Stem Cells (HESC) industry.

The global Human Embryonic Stem Cells (HESC) market depends on different factors that can either be a positive influence on the global market or cause the market to decline. The factors are identified and are categorized based on the effect that they can have on the market. The various factors are identified across all market segments and the different regions that are mentioned in the report.

Get Free Sample PDF (including COVID19 Impact Analysis, full TOC, Tables and Figures): About Us: https://www.datalibraryresearch.com/sample-request/human-embryonic-stem-cells-hesc-market-2728?utm_source=unlvrebelyell&utm_medium=41

The objective of the study is to define market sizes of different segments and countries in previous years and to forecast the values to the next Five years. The report is designed to incorporate both qualify qualitative and quantitative aspects of the industry with respect to each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as drivers and restraining factors which will define the future growth of the Human Embryonic Stem Cells (HESC) market.

Some of The Companies Competing in The Human Embryonic Stem Cells (HESC) Market are Astellas Institute of Regenerative Medicine, Asterias Biotherapeutics Inc., BD Biosciences, Cell Cure Neurosciences Ltd. (Israel),Cellular Dynamics International,GE Healthcare (UK), MilliporeSigma, PerkinElmer Inc., Reliance Life Sciences Ltd. (India),Research and Diagnostics Systems Inc., SABiosciences Corp.

It takes into account the CAGR, value, volume, revenue, production, consumption, sales, manufacturing cost, prices, and other key factors related to the global Human Embryonic Stem Cells (HESC) market. All findings and data on the global Human Embryonic Stem Cells (HESC) market provided in the report are calculated, gathered, and verified using advanced and reliable primary and secondary research sources. The regional analysis offered in the report will help you to identify key opportunities of the global Human Embryonic Stem Cells (HESC) market available in different regions and countries.

Market Analysis, Insights and Forecast By Type

Totipotent Stem Cell Pluripotent Stem Cell Unipotent Stem Cell

Market Analysis, Insights and Forecast By Application

Regenerative medicine Stem cell biology research Tissue engineering Toxicology testing

Do You Have Any Query Or Specific Requirement? Ask to Our IndustryExpert@ https://www.datalibraryresearch.com/enquiry/human-embryonic-stem-cells-hesc-market-2728?utm_source=unlvrebelyell&utm_medium=41

The study objectives of this report are:

To study and analyze the global Human Embryonic Stem Cells (HESC) consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2028.

To understand the structure of Human Embryonic Stem Cells (HESC) market by identifying its various subsegments.

Focuses on the key global Human Embryonic Stem Cells (HESC) manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.

To analyze the Human Embryonic Stem Cells (HESC) with respect to individual growth trends, future prospects, and their contribution to the total market.

To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).

To project the consumption of Human Embryonic Stem Cells (HESC) submarkets, with respect to key regions (along with their respective key countries).

To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

To strategically profile the key players and comprehensively analyze their growth strategies.

About Us:

Data Library Research is a market research company that helps to find its passion for helping brands grow, discover, and transform. We want our client to make wholehearted and long term business decisions. Data Library Research is committed to deliver their output from market research studies which are based on fact-based and relevant research across the globe. We offer premier market research services that cover all industries verticals, including agro-space defense, agriculture, and food, automotive, basic material, consumer, energy, life science, manufacturing, service, telecom, education, security, technology. We make sure that we make an honest attempt to provide clients an objective strategic insight, which will ultimately result in excellent outcomes.

Contact Us:Rohit Shrivas,Senior Manager International Sales and MarketingData Library Researchinfo@datalibraryresearch.comPh: +13608511343 (US)www.datalibraryresearch.com

Go here to read the rest:
Human Embryonic Stem Cells (HESC) Market Updates to 2021: Brief, Trends, Applications, Types, Research, Forecast to 2028 UNLV The Rebel Yell - UNLV...

Read More...

Page 206«..1020..205206207208..220230..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick